Dynavax Technologies (NASDAQ:DVAX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Thursday.

According to Zacks, “Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax’s clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. “

Several other equities research analysts have also recently commented on DVAX. BidaskClub cut Dynavax Technologies from a “sell” rating to a “strong sell” rating in a report on Monday, February 25th. ValuEngine cut Dynavax Technologies from a “hold” rating to a “sell” rating in a report on Monday, February 4th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $28.00 price target (down previously from $32.00) on shares of Dynavax Technologies in a report on Tuesday, February 26th. Three analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $27.00.

Shares of NASDAQ:DVAX traded up $0.03 during midday trading on Thursday, hitting $7.56. The company had a trading volume of 1,064,281 shares, compared to its average volume of 1,112,319. Dynavax Technologies has a twelve month low of $7.32 and a twelve month high of $22.80. The company has a debt-to-equity ratio of 1.60, a quick ratio of 4.08 and a current ratio of 4.58. The stock has a market cap of $476.16 million, a PE ratio of -2.96 and a beta of 0.70.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Tuesday, February 26th. The biopharmaceutical company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.04). Dynavax Technologies had a negative net margin of 1,938.27% and a negative return on equity of 139.00%. The company had revenue of $3.90 million during the quarter, compared to analyst estimates of $3.43 million. During the same period in the prior year, the business posted ($0.45) EPS. Dynavax Technologies’s revenue for the quarter was up 18471.4% compared to the same quarter last year. As a group, analysts predict that Dynavax Technologies will post -2.1 earnings per share for the current fiscal year.

In other Dynavax Technologies news, insider Michael S. Ostrach sold 35,444 shares of the firm’s stock in a transaction on Thursday, February 28th. The stock was sold at an average price of $8.94, for a total transaction of $316,869.36. Following the completion of the sale, the insider now owns 121,581 shares of the company’s stock, valued at $1,086,934.14. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Robert Coffman sold 63,202 shares of the firm’s stock in a transaction on Thursday, February 28th. The stock was sold at an average price of $9.03, for a total value of $570,714.06. Following the sale, the senior vice president now directly owns 86,268 shares of the company’s stock, valued at approximately $779,000.04. The disclosure for this sale can be found here. In the last ninety days, insiders sold 119,411 shares of company stock valued at $1,075,091. Insiders own 3.47% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC increased its stake in Dynavax Technologies by 9.6% during the fourth quarter. Geode Capital Management LLC now owns 650,953 shares of the biopharmaceutical company’s stock worth $5,956,000 after acquiring an additional 57,082 shares during the last quarter. FMR LLC increased its stake in Dynavax Technologies by 39.1% during the fourth quarter. FMR LLC now owns 2,055,785 shares of the biopharmaceutical company’s stock worth $18,810,000 after acquiring an additional 577,868 shares during the last quarter. Millennium Management LLC increased its stake in Dynavax Technologies by 513.7% during the fourth quarter. Millennium Management LLC now owns 614,930 shares of the biopharmaceutical company’s stock worth $5,627,000 after acquiring an additional 514,736 shares during the last quarter. Wall Street Access Asset Management LLC increased its stake in Dynavax Technologies by 7.0% during the fourth quarter. Wall Street Access Asset Management LLC now owns 15,300 shares of the biopharmaceutical company’s stock worth $140,000 after acquiring an additional 1,000 shares during the last quarter. Finally, Macquarie Group Ltd. acquired a new stake in Dynavax Technologies during the fourth quarter worth $4,575,000. 88.07% of the stock is owned by institutional investors.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.

Read More: Return on Equity (ROE)

Get a free copy of the Zacks research report on Dynavax Technologies (DVAX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.